KR880001292A - 자가면역병 치료를 위한 브로모크립틴의 단독 요법 - Google Patents

자가면역병 치료를 위한 브로모크립틴의 단독 요법 Download PDF

Info

Publication number
KR880001292A
KR880001292A KR1019870007490A KR870007490A KR880001292A KR 880001292 A KR880001292 A KR 880001292A KR 1019870007490 A KR1019870007490 A KR 1019870007490A KR 870007490 A KR870007490 A KR 870007490A KR 880001292 A KR880001292 A KR 880001292A
Authority
KR
South Korea
Prior art keywords
diabetes mellitus
disease
bromocriptine
glomerulosclerosis
graves
Prior art date
Application number
KR1019870007490A
Other languages
English (en)
Inventor
다글라스 랄슨 닥터.
히슈탄트 페터
Original Assignee
제랄드 디. 샤르킨
산도즈 파마슈티칼스 코오포레이숀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제랄드 디. 샤르킨, 산도즈 파마슈티칼스 코오포레이숀 filed Critical 제랄드 디. 샤르킨
Publication of KR880001292A publication Critical patent/KR880001292A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

자가면역병 치료를 위한 브로모크립틴의 단독 요법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 브로모크립틴의 효과적인 양을 환자에게 투여하는 것을 특징으로 하여 하기의 그룹에서 선택된 병을 치료하는 방법.
    a) 중증성 근무력증 ; b) 내분비성 눈병 ; c) 그레이브스병 ; d) 소아 당뇨병(진상 당뇨병 타입Ⅰ) ; e) 사구체 경화증(네프로제 증후군 증상의 유무에 관계없이); f) 전신 홍반성 낭창 ; g) 자가면역 혈액 장애 ; h) 다발성 경화증 ; i) 자가면역에 의한 장염병.
  2. 하기의 그룹에서 선택된 병치료에 브로모크립틴을 사용하는 방법.
    a) 중증성 근무력증 ; b) 내분비성 눈병 ; c) 그레이브스병 ; d) 소아 당뇨병(진상 당뇨병 타입Ⅰ) ; e) 사구체 경화증(네프로제 증후군 증상의 유무에 관계없이) ; f) 전신 홍반성 낭창 ; g) 자가면역 혈액 장애 ; h) 다발성 경화증 ; i) 자가면역에 의한 장염병.
  3. 하기의 그룹에서 선택된 병치료를 위한 약학적 조성물 제조에 브로모크립틴을 사용하는 방법.
    a) 중증성 근무력증 ; b) 내분비성 눈병 ; c) 그레이브스병 ; d) 소아 당뇨병(진상 당뇨병 타입Ⅰ) ; e) 사구체 경화증(네프로제 증후군 증상의 유무에 관계없이) ; f) 전신 홍반성 낭창 ; g) 자가면역 혈액 장애 ; h) 다발성 경화증 ; i) 자가면역에 의한 장염병.
  4. 하기의 그룹에서 선택된 병치료를 위해 활성제로서 브로모크립틴을 함유하는 약학적 조성물.
    a) 중증성 근무력증 ; b) 내분비성 눈병 ; c) 그레이브스병 ; d) 소아 당뇨병(진상 당뇨병 타입Ⅰ) ; e) 사구체 경화증(네프로제 증후군 증상의 유무에 관계없이) ; f) 전신 홍반성 낭창 ; g) 자가면역 혈액장애 ; h) 다발성 경화증 ; i) 자가면역에 의한 장염병.
  5. 제4항에 있어서, 브로모 크립틴은 브로모 크립틴 메실레이트인 것을 특징으로 하는 약학적 조성물.
  6. 제4항에 있어서, 유니트 용량당 브로모 크립틴 2.5-10㎎을 함유하는 것을 특징으로 하는 약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870007490A 1986-07-14 1987-07-13 자가면역병 치료를 위한 브로모크립틴의 단독 요법 KR880001292A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88511086A 1986-07-14 1986-07-14
US885110 1986-07-14

Publications (1)

Publication Number Publication Date
KR880001292A true KR880001292A (ko) 1988-04-22

Family

ID=25386156

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870007490A KR880001292A (ko) 1986-07-14 1987-07-13 자가면역병 치료를 위한 브로모크립틴의 단독 요법

Country Status (13)

Country Link
JP (1) JPS6323817A (ko)
KR (1) KR880001292A (ko)
AU (1) AU602154B2 (ko)
CH (1) CH672987A5 (ko)
DE (1) DE3722383A1 (ko)
DK (1) DK363887A (ko)
FR (1) FR2601245A1 (ko)
GB (1) GB2192541B (ko)
IT (1) IT1224222B (ko)
NL (1) NL8701631A (ko)
PH (1) PH24525A (ko)
SE (1) SE8702843L (ko)
ZA (1) ZA875145B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3814521A1 (de) * 1987-05-07 1988-11-17 Sandoz Ag Neue anwendung von dopaminrezeptor-agonisten
EP0327040A3 (de) * 1988-02-05 1990-11-28 Predrag Dr.Sc. Sikiric Verwendung von Dopamin und/oder von Dopamin-Agonisten zur Herstellung eines Arzneimittels für die Behandlung des Verdauungstrakts
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5716932A (en) * 1988-05-10 1998-02-10 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5700800A (en) * 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5585347A (en) * 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5744477A (en) * 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US5830895A (en) * 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
CZ282909B6 (cs) * 1991-12-23 1997-11-12 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Použití agonisty dopaminu a stimulátoru prolaktinu pro přípravu farmaceutického přípravku a tento farmaceutický přípravek
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US5714519A (en) * 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US5626860A (en) * 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
SI2091537T1 (sl) * 2006-11-23 2013-10-30 Sinoxa Pharma Gmbh Farmacevtski sestavki za zdravljenje kapilarne arteriopatije
ES2897475T3 (es) * 2016-04-20 2022-03-01 Veroscience Llc Composición y método para el tratamiento de trastornos metabólicos
EP4233913A3 (en) 2017-10-18 2023-10-18 VeroScience LLC Improved bromocriptine formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions

Also Published As

Publication number Publication date
NL8701631A (nl) 1988-02-01
SE8702843L (sv) 1988-01-15
JPS6323817A (ja) 1988-02-01
CH672987A5 (ko) 1990-01-31
GB2192541B (en) 1990-05-02
PH24525A (en) 1990-07-18
FR2601245A1 (fr) 1988-01-15
DE3722383A1 (de) 1988-01-28
DK363887A (da) 1988-01-15
AU7558787A (en) 1988-01-21
IT8748160A0 (it) 1987-07-10
DK363887D0 (da) 1987-07-13
SE8702843D0 (sv) 1987-07-13
GB2192541A (en) 1988-01-20
IT1224222B (it) 1990-09-26
GB8716323D0 (en) 1987-08-19
ZA875145B (en) 1989-02-22
AU602154B2 (en) 1990-10-04

Similar Documents

Publication Publication Date Title
KR880001292A (ko) 자가면역병 치료를 위한 브로모크립틴의 단독 요법
Goadsby et al. Oral sumatriptan in acute migraine
DK0594607T3 (da) Forøgelse af nedreguleringen af autoimmune sygdomme ved oral eller enteral indgivelse af autoantigener
NO931267D0 (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
ATE50260T1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
US4590213A (en) Anti-anxiety method
KR850700109A (ko) 항 이뇨제 ddavp 및 그의 제조 방법
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
EP0482089A4 (en) Methods of treating or preventing autoimmune uveoretinitis in mammals
KR890006227A (ko) 페놀-함유 진해성 액체 조성물
Alvan Effect of activated charcoal on plasma levels of nortriptyline after single doses in man
FR2456104A1 (fr) Nouvelles pyrazinobenzodiazepines, leur preparation et leur application comme medicaments
KR890004705A (ko) 항바이러스성 제제
Brenner et al. Serratia marcescens cellulitis
KR890007728A (ko) 진통제 제조방법
WO1995000154B1 (en) Antidepressant agents with a rapid onset of action
KR880002521A (ko) 약제 제형
Ananth et al. Intramuscular lorazepam: A double-blind comparison with diazepam and placebo
KR950700063A (ko) 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)
KR880003623A (ko) 시알로실글리세로리피드로 된 신경장해질환 치료제
Kanchanomai Disposition of sulfonamides in cattle: A determination of sulfamonomethoxine level in blood in cattle following the intravenous and subcutaneous administration
Mazur Effects of caffeine and ethanol on the level of these agents in rat blood serum.
Furuse et al. Effects of tritoqualine of paraquat poisoning

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid